Improving heart failure outcomes, whatever the ejection fraction

+Practice
In print
Heartbeat

Improving heart failure outcomes, whatever the ejection fraction

Chris Ellis

Chris Ellis

Heartbeat-ECG-Jun-2025
ECG supplied

Consultant cardiologist Chris Ellis discusses the use of a relatively new medicine for patients with heart failure. Benefits are evident with reduced and preserved ejection fractions

Key points, Empagliflozin is funded for some patients with heart failure (NYHA class II, III or IV with ejection fraction ≤40 per cent) via a Special Authority ap, Pract Green w Pale Yellow
References

1. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–24.

2. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–61.